中国医学创新2024，Vol.21Issue(16)：16-20,5.DOI:10.3969/j.issn.1674-4985.2024.16.004
左西孟旦联合沙库巴曲缬沙坦钠在急性前壁心肌梗死PCI术后早期应用的临床研究
Clinical Study on the Early Application of Levosimendan Combined with Sacubitril Valsartan Sodium in Acute Anterior Myocardial Infarction after PCI
摘要
Abstract
Objective:To explore the application effect of early application of Levosimendan combined with Sacubitril Valsartan Sodium in acute anterior myocardial infarction after percutaneous coronary intervention(PCI).Method:A total of 120 patients with early heart failure after PCI for acute anterior myocardial infarction admitted to Department of Cardiovascular Medicine,Pingxiang People's Hospital from September 2021 to September 2023 were selected and divided into observation group(n=60)and control group(n=60)by random number table method.The control group was treated with Sacubitril Valsartan Sodium,and the observation group was treated with Levosimendan combined with Sacubitril Valsartan Sodium,both groups were treated for 7 days.The clinical efficacy,cardiac function and ventricular remodeling indexes,serological indexes and adverse reactions were compared between the two groups.Result:The total effective rate of observation group was higher than that of control group(P<0.05).After treatment,left ventricular ejection fraction(LVEF)in both groups increased compared with that before treatment,and that in the observation group was higher,left ventricular end-systolic diameter(LVESD),left ventricular end-diastolic diameter(LVEDD),interventricular septal thickness(IVST)and left ventricular posterior wall thickness(LVPWT)in both groups decreased compared with those before treatment,and those in the observation group were lower(P<0.05).After treatment,the N-terminal probrain natriuretic peptide(NT-proBNP)and C reactive protein(CRP)in both groups were decreased compared with those before treatment,and those in the observation group were lower(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Levosimendan combined with Sacubitril Valsartan Sodium is effective in patients with early heart failure after PCI for acute anterior myocardial infarction,can improve cardiac function and ventricular remodeling,inhibit inflammatory response,and is safe and reliable.关键词
急性前壁心肌梗死/经皮冠状动脉介入治疗/心力衰竭/左西孟旦/沙库巴曲缬沙坦钠Key words
Acute anterior myocardial infarction/Percutaneous coronary intervention/Heart failure/Levosimendan/Sacubitril Valsartan Sodium引用本文复制引用
刘兴龙,姚常,罗勤,周国忠,黄文军..左西孟旦联合沙库巴曲缬沙坦钠在急性前壁心肌梗死PCI术后早期应用的临床研究[J].中国医学创新,2024,21(16):16-20,5.基金项目
江西省卫生健康委科技计划项目(SKJP220218236) （SKJP220218236）
